P/E ratio for AstraZeneca (AZN)

P/E ratio history for AstraZeneca from 2009 to 2025

PE ratio at the end of each year

P/E ratio for similar companies or competitors

Company	P/E ratio	P/E ratio differencediff.	Country
Johnson & Johnson JNJ	22.9	-36.42%	🇺🇸 USA
Novartis NVS	21.2	-41.32%	🇨🇭 Switzerland
Pfizer PFE	15.8	-56.17%	🇺🇸 USA
Abbott Laboratories ABT	13.6	-62.23%	🇺🇸 USA
Eli Lilly LLY	51.1	41.46%	🇺🇸 USA
Sanofi SNY	12.9	-64.22%	🇫🇷 France
Biogen BIIB	18.0	-50.03%	🇺🇸 USA
Merck MRK	16.1	-55.42%	🇺🇸 USA
Bristol-Myers Squibb BMY	20.8	-42.30%	🇺🇸 USA
GSK plc GSK	16.7	-53.62%	🇬🇧 UK

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.